紫杉醇脂质体联合奈达铂治疗局部中晚期食管鳞癌效果观察  

Clinical efficacy of paclitaxel liposome combined with nedaplatin for locally advanced esophageal squamous carcinoma

作　　者：任亚丽[1] 吴伟[1] 顾玮 潘敏侠 朱玉萍[2] Ren Yali;Wu Wei;Gu Wei(Nantong Health Branch of Jiangsu Union Technical Institute,Nantong 226010)

机构地区：[1]江苏联合职业技术学院南通卫生分院,江苏南通226010 [2]南通瑞慈医院

出　　处：《中国现代医药杂志》2020年第3期15-19,共5页Modern Medicine Journal of China

基　　金：2018年度南通市卫生和计划生育委员会立项课题(编号:WKZL2018080);江苏高校“青蓝工程”资助项目。

摘　　要：目的探讨奈达铂替代顺铂联合紫杉醇脂质体治疗局部中晚期食管鳞癌的疗效及其毒副反应.方法80例局部中晚期食管鳞癌患者随机分为紫杉醇脂质体联合顺铂组(TP组)和紫杉醇脂质体联合奈达铂组(TN组).化疗每28d为1个疗程,共2个疗程.结果TN组治疗有效率为52.50%,TP组为37.50%,两组比较差异无统计学意义(P>0.05);TN组生存质量高于TP组(P<0.05);TN组中位生存期为(18.70±10.69)个月,TP组为(16.33±9.99)个月,两组比较差异无统计学意义(P>0.05);TN组肾功能损伤、恶心呕吐、腹泻的发生率分别为5.00%、22.50%、10.00%,与TP组的22.50%、45.00%、27.50%比较差异有统计学意义(P<0.05),两组在白细胞、中性粒细胞和血小板的减少以及脱发的发生率上差异无统计学意义(P>0.05).结论紫杉醇脂质体联合奈达铂治疗局部中晚期食管癌的不良反应发生率低,效果显著.Objective To investigate the efficacy and side effect of nedaplatin instead of cisplatin combined with paclitaxel liposome in the treatment of locally advanced esophageal squamous carcinoma.Methods 80 patients with locally advanced esophageal squamous carcinoma were randomly divided into paclitaxel liposome combined with cisplatin group(TP group)and paclitaxel liposome combined with nedaplatin group(TN group).Chemotherapy took 1 course every 28 days,2 courses in total.Results The effective rate of TN group and TP group was 52.50%and 37.50%respectively.There was no significantly statistical difference(P>0.05).The quality of life in TN group was higher than that in TP group(P<0.05).The median survival time of TN group was(18.70±10.69)months,and that of TP group was(16.33±9.99)months,there was no significantly statistical difference(P>0.05).The incidence rate of renal function injury,diarrhea,nausea and vomiting in TN group was 5.00%,22.50%and 10.00%respectively,which was significantly different from TP group(22.50%,45.00%,27.50%)(P<0.05).There was no significant difference in the incidence rate of leukopenia,neutropenia,thrombocytopenia and alopecia between the two groups(P>0.05).Conclusion Paclitaxel liposome combined with nedaplatin can reduce the incidence of adverse reactions,it has significant effect in the treatment of locally advanced esophageal cancer.

关 键 词：紫杉醇脂质体 奈达铂 顺铂 食管癌 

分 类 号：R735.1[医药卫生—肿瘤]